HormonesResearch PaperPaywall

US Menopause Hormone Therapy Dispensing Trends by Age, Formulation and Route

A JAMA analysis of national pharmacy data tracks how menopause hormone therapy is dispensed in the US by age, formulation and route.

Friday, November 20, 2026 1 view
Published in JAMA
a pharmacist's hands holding a prescription box of estrogen patches at a pharmacy counter

Summary

Menopause hormone therapy (MHT) is a major tool for managing menopause symptoms, and it is also discussed in relation to bone, heart and brain aging. This JAMA research letter used national pharmacy dispensing data to look at how MHT is actually being dispensed in the US, broken down by age group, formulation and route of delivery (for example pills versus patches, gels or vaginal products). Only the abstract was available to us, and it gives the study design and the questions asked but no numbers or results. We therefore cannot say whether dispensing is rising or falling, or which products or age groups are driving any change. Dispensing data show what is prescribed and filled, not who benefits or whether outcomes improve. The paper is worth reading in full for the actual figures. It describes real-world practice, not the effects of hormone therapy on health, and it does not test any mechanism.

Detailed Summary

Why this matters: Menopause hormone therapy sits at the center of debates about women's healthspan. It relieves hot flashes and other symptoms, and its effects on bone, cardiovascular risk, brain health and breast cancer risk have shaped prescribing for two decades. How therapy is used in practice, including at what age and by which route, matters because risks and benefits differ by timing, formulation and delivery method.

What was studied: Sarnak, Shen and Alexander, from Johns Hopkins, published a cross-sectional study in JAMA that uses national US pharmacy dispensing data. The abstract says it examines MHT dispensing overall and by age group, formulation and route of administration.

Key results: The abstract available to us does not report any numerical results. We cannot state trends, percentages, which formulations are rising or falling, or how dispensing differs between age groups. Any specific claim about direction or magnitude would go beyond the source, so none is made here.

Implications: Dispensing data are a useful window into real-world practice. They can show whether prescribing is shifting toward particular routes, such as transdermal versus oral, or toward particular age groups, and so whether practice is tracking evolving evidence. That matters to clinicians and to women weighing hormone therapy. The study itself does not test a mechanism or measure health outcomes, so it cannot show whether any prescribing pattern is beneficial or harmful.

Caveats: This summary rests on the abstract only, since the full paper is not open access. Pharmacy dispensing data record filled prescriptions, not use, adherence, indication or outcomes. Cross-sectional designs describe patterns and cannot establish cause. Readers should consult the full JAMA paper for the actual findings before drawing any conclusions about prescribing trends.

Key Findings

  • Design: cross-sectional analysis of national US pharmacy dispensing data on menopause hormone therapy.
  • Dispensing was examined by age group, formulation and route of administration.
  • The abstract reports no numerical results, so trend direction and size cannot be stated.
  • No mechanism, function or lifespan outcome was tested; this is a descriptive practice-pattern study.

Methodology

Cross-sectional study using national pharmacy dispensing data, published as a JAMA research letter. Stratified by age group, formulation and route. Sample size, data source name and time window are not given in the abstract.

Study Limitations

This summary is based on the abstract only, which contains no quantitative results. Dispensing data capture filled prescriptions, not adherence, indications or health outcomes. A cross-sectional design cannot show causation or effects on healthspan.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: